Edgewise Therapeutics (NASDAQ:EWTX) Earns Buy Rating from Analysts at Guggenheim
Guggenheim initiated coverage on shares of Edgewise Therapeutics (NASDAQ:EWTX – Get Free Report) in a research report issued to clients and investors on Wednesday, Marketbeat.com reports. The firm set a “buy” rating and a $41.00 price target on the stock. Guggenheim’s price target suggests a potential upside of 145.80% from the stock’s current price. Other […]
Guggenheim initiated coverage on shares of Edgewise Therapeutics (NASDAQ:EWTX – Get Free Report) in a research report issued to clients and investors on Wednesday, Marketbeat.com reports. The firm set a “buy” rating and a $41.00 price target on the stock. Guggenheim’s price target suggests a potential upside of 145.80% from the stock’s current price. Other […]
